Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
<< anterior 21 a 40 de 276 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016:28 de junio. [Ref.ID 100445]
22.Tiene citas relacionadas Cita con resumen
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-90. [Ref.ID 100239]
23.Tiene citas relacionadas Cita con resumen
Waters DD, Hsue PY, Bangalore S. PCSK9 inhibitors for statin intolerance?. JAMA 2016;315:1571-2. [Ref.ID 100238]
24. Cita con resumen
Anónimo. Two new lipid-regulating drugs. Drug Ther Bull 2016;54:18-21. [Ref.ID 100095]
25. Cita con resumen
Levin S, Wells C, Barnard N. Dietary Cholesterol and Blood Cholesterol Concentrations. JAMA 2015;314:2083-4. [Ref.ID 99688]
26. Cita con resumen
Jarcho JA, Keaney JF Jr. Proof that lower is better - LDL cholesterol and IMPROVE-it. N Engl J Med 2015;372:2448-58. [Ref.ID 99299]
27. Cita con resumen
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzylio W, De Lucca P, Im K, Bohula EA, Reist CJ, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. [Ref.ID 99298]
29.Tiene citas relacionadas Cita con resumen
The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12. [Ref.ID 97194]
30.Tiene citas relacionadas Cita con resumen
33. Cita con resumen
Hiatt WR, Smith RJ. Assessing the clinical benefits of lipid-disorder. N Engl J Med 2014;370:396-9. [Ref.ID 97063]
34.Tiene citas relacionadas Cita con resumen
Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, Guzmán L, Linares JC, García F, D'Aniello F, Arnáiz JA, Varea S, Martínez F, Lorenzatti A, Imaz I, Sánchez-Gómez LM, Roncaglioni MC, Baviera M, Smith Jr SC, Taubert K. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014;64:2071-82. [Ref.ID 97057]
35.Tiene citas relacionadas Cita con resumen
Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013;310:2061-8. [Ref.ID 96573]
36.Tiene citas relacionadas Cita con resumen
Gaziano JM, Gaziano TA. What's new with measuring cholesterol?. JAMA 2013;310:2043-944. [Ref.ID 96571]
37.Enlace a cita original Cita con resumen
Brett AS. Lipid-modifying therapy: a new paradigm. Journal Watch 2013:12 de noviembre. [Ref.ID 96285]
39. Cita con resumen
Morden NE, Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med 2013;369:299-302. [Ref.ID 95875]
Seleccionar todas
 
<< anterior 21 a 40 de 276 siguiente >>